Ascletis receives China NMPA approval, to begin phase IIa trial to treat RSV infection
Ascletis Pharma Inc. announces that the China National Medical Products Administration (NMPA) has approved to conduct a phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection. Based on available data, dosage of 800 mg ASC10, twice daily was selected to conduct a randomized, double-blind, placebo-controlled phase IIa study to evaluate the antiviral activity, safety, tolerability and pharmacokinetics of ASC10 tablets in patients with mild or moderate RSV infection.
